Dr. Konopleva's research focus is on studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs.
MD Anderson Cancer Center:
1515 Holcombe Blvd, Houston, TX 77030, USA
Get the latest thought leadership on AML delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life
AML stories, AML clinical trials, AML 101 articles and events with AML
Thanks to our HealthTree Community for AML Sponsors: